ReviewFrontiers in oncology2026
Precision oncology in gynecologic cancers: molecular taxonomy, biomarker-guided therapeutics, and the challenge of therapeutic resistance.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The clinical management of gynecologic malignancies endometrial (EC), ovarian (OC), and cervical (CC) carcinomas has been historically guided by histomorphology and staging. This paradigm fails to capture profound molecular heterogeneity, resulting in suboptimal outcomes. Precision oncology, through molecular taxonomy and biomarker-guided therapy, aims to address this gap. Methods: This review synthesizes the current landscape of precision oncology in gynecologic cancers by analyzing established molecular classifications, the evidence for biomarker-guided therapies, mechanisms of therapeutic resistance, and emerging diagnostic and trial paradigms. The analysis is based on a critical evaluation of key literature and clinical trial data. Results: Molecular reclassification, exemplified by The Cancer Genome Atlas (TCGA) for EC and OC, has identified prognostically and therapeutically relevant subtypes. This has enabled successful clinical translation of targeted agents: PARP inhibitors for homologous recombination deficient (HRD) ovarian cancer, immune checkpoint inhibitors for mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) endometrial and cervical cancers, and antibody-drug conjugates (ADCs) like mirvetuximab soravtansine and tisotumab vedotin. However, acquired resistance to these therapies, driven by tumor evolution and heterogeneity, remains a pivotal barrier. Conclusion: The convergence of deep molecular phenotyping with targeted therapy is a cornerstone of modern care. Future directions require overcoming resistance through novel diagnostics like liquid biopsy, next-generation therapeutics, and innovative adaptive clinical trials. Equitable access to these advances is imperative to prevent widening health disparities. The field is evolving towards a model of continuous molecular monitoring and adaptive therapy to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.